Danette Daniels Ph.D is a Vice President of the Protein Degrader Platform at Foghorn Therapeutics developing therapeutic degraders in the areas of chromatin regulation and oncology. She was an early leader in the field of targeted protein degradation, pioneering approaches to monitor cellular kinetics of degradation, understand mechanism of action, and most recently, co-developing a new PROTAC modality during her previous position as a R&D Group Leader at Promega Corporation.
Danette Daniels Ph.D
Vice President of the Protein Degrader Platform at Foghorn Therapeutics
